Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit – Markets Insider
|
Poseida Therapeutics Presents Novel BCMA-Specific CAR–T Therapy at CAR-TCR Summit
Markets Insider SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving cell therapies, today presented preclinical data on P-BCMA-101, the … |
|
Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release …
Markets Insider “The clinical success and recent regulatory approval of the first CAR T-cell therapy has shown the efficacy of CAR T-cell technologies in hematological malignancies and the potential promise of the treatment in solid tumors as well. However, these … |
|
CAR–T
STAT CAR-T is short for chimeric antigen receptor T–cell. CAR-T therapies could be considered a subset of immunotherapy. They’re also a subset of cellular therapies. (But not of gene therapy, some biotech types have 2 loudly 3 declared 4.) Here’s how they … |